Analytical Data
-
Gene name
Eotaxin-3/CCL26
- Application
-
Alternative Names
CC chemokine IMAC, Macrophage inflammatory protein 4-alpha, MIP-4-alpha, Small-inducible cytokine A26, Thymic stroma chemokine-1
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 97% as determined by SDS-PAGE.
-
Uniprot
Q9Y258
-
Expression Region
24-94aa
-
Protein Length
Partial
-
Molecular Weight
8.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Eotaxin-3, also known as CCL26, is a chemokine that plays a crucial role in the recruitment of eosinophils, a type of white blood cell involved in allergic responses and asthma. It is primarily produced by epithelial cells in various tissues, particularly in the lungs and gastrointestinal tract. The study of Eotaxin-3/CCL26 has gained significant attention due to its potential involvement in various inflammatory conditions, including allergic rhinitis, asthma, and certain gastrointestinal disorders. Elevated levels of Eotaxin-3 have been correlated with the severity of these diseases, indicating its role in the pathophysiology of eosinophil-driven inflammation. As a result, Eotaxin-3 has emerged as a promising target for therapeutic intervention. Research on recombinant Eotaxin-3/CCL26 focuses on understanding its molecular mechanisms, interaction with receptors such as CCR3, and its effects on immune cell trafficking. By exploring these aspects, scientists aim to develop targeted therapies that can modulate eosinophilic inflammation, potentially offering new treatment strategies for patients suffering from eosinophil-associated diseases. This research not only enhances our understanding of immune responses but also provides insights into the development of innovative therapies aimed at alleviating the burden of these chronic inflammatory conditions.
